Absci Corp
For the period ended Dec 31, 2025. Filed Mar 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to the Consolidated Financial Statements
- Organization and nature of operations
Absci Corporation (the “Company”) is a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody-based therapeutics .
The Company was organized in the State of Oregon in August 2011 as a limited liability company and converted to a limited liability company (“LLC”) in Delaware in April 2016. In October 2020, the Company converted from a Delaware LLC to a Delaware corporation. The Company’s headquarters are located in Vancouver, Washington.
- Summary of significant accounting policies
Basis of presentation
The consolidated financial statements are prepared in accordance with US GAAP as defined by the Financial Accounting Standards Board (“FASB”). The consolidated financial statements include the Company’s wholly-owned subsidiaries and entities under its control. The Company has eliminated all intercompany transactions and accounts. Certain amounts in prior years' financial statements have been reclassified to conform to the current year's presentation.
Use of estimates
The preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, revenue recognition including estimated timing of the satisfaction of performance obligations, the fair value of stock-based compensation awards, and evaluations of recoverability of long-lived assets. The Company bases its estimates on historical experiences, and other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Segment information
The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating performance (see Note 16: Segment Reporting).
Cash, cash equivalents and restricted cash
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking and interest-bearing accounts, highly liquid money market funds, and U.S. Treasury securities.
Restricted cash represents amounts pledged as collateral for future property lease payments via standby letters of credit (see Note 11: Commitments and contingencies) and amounts formerly held in escrow related to acquisitions by the Company (see Note 6: Fair value measurements).
Investments
The Company’s marketable securities may include funds invested in highly liquid money market funds, U.S. Treasury securities and corporate debt securities. The Company considers all marketable securities to be current assets as they are available for use in current operations. These investments are classified as available-for-sale debt securities, which are recorded at fair value based on quoted prices in active markets.
If the estimated fair value of a debt security is below its amortized cost basis, the Company evaluates whether it is more likely than not that the Company will be required to sell the security before its anticipated recovery in market value and whether credit losses exist for the related securities. A credit loss exists if the present value of expected cash flows is less than the amortized cost basis of the security. Credit-related losses are recognized as an allowance for credit losses on the balance sheet with a corresponding adjustment to earnings. Unrealized gains and losses that are unrelated to credit deterioration are reported in accumulated other comprehensive income (loss) on the consolidated balance sheets. Purchase premiums and discounts are recognized as interest income using the interest method over the terms of the securities. Realized gains and losses, and declines in fair value deemed to be other than temporary, are reflected in the consolidated statements of operations and comprehensive loss. The Company uses the specific identification method to compute realized gains and losses on investments. Investments in non-marketable equity securities are classified as other long-term assets on the consolidated balance sheets.
Fair value of financial instruments
Certain assets and liabilities are carried at fair value under US GAAP. The carrying amounts of cash equivalents, accounts payable, and accrued liabilities approximate their related fair values due to the short-term nature of these instruments. The Company measures certain financial assets at fair value on a recurring basis, including available-for-sale debt securities, which are recorded at fair value based on quoted prices in active markets. None of the Company’s non-financial assets or liabilities are recorded at fair value on a recurring basis.
Concentration risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, and accounts receivable. The Company maintains its cash and cash equivalents and restricted cash in bank accounts, which at times may exceed federally insured limits. The Company has not experienced any losses on these accounts.
Property and equipment, net
Property and equipment are stated at cost less accumulated depreciation and amortization. Additions and improvements to property and equipment are capitalized. The costs of maintenance and repairs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the underlying assets, which vary from 3 to 7 years. Leasehold improvements are amortized over the shorter of the term of the lease or the estimated useful lives of the assets. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation or amortization are removed from their respective accounts, and the resulting gain or loss is reported as operating expense in the consolidated statements of operations and comprehensive loss.
Assets held for sale
The Company classifies its long-lived assets to be sold as held for sale in the period the following conditions are met: (i) management has approved and committed to a plan to sell; (ii) the asset is available for immediate sale in its present condition; (iii) an active program to locate a buyer and other actions required to sell the asset have been initiated; (iv) it is probable that a sale will occur within one year; (v) the asset is being actively marketed for sale at a reasonable price in relation to its current fair value; and (vi) there is a low likelihood of significant changes to the plan or that the plan will be withdrawn. If all of the criteria are met as of the balance sheet date, the assets are presented separately as held for sale included in prepaid and other current assets on the consolidated balance sheets. The Company initially measures a long-lived asset that is classified as held for sale at the lower of the carrying amount or fair value less costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met as an asset impairment charge on the consolidated statements of operations and comprehensive loss. Any gains are not recognized until date of sale. The assets are no longer depreciated nor amortized while classified as held for sale. The Company assesses the fair value of a long-lived asset, less any costs to sell, at each reporting period and until the asset is no longer classified as held for sale.
Impairment of long-lived assets
Management reviews long-lived assets for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows expected to result from the use of the asset and its eventual disposition. If these estimated cash flows were less than the carrying amount of the asset, an impairment loss would be recognized in order to write down the asset to its estimated fair value and reported as operating expense in the consolidated statements of operations and comprehensive loss.
Revenue recognition
The Company recognizes revenue as control of its products and services are transferred to its customers in an amount that reflects the consideration expected to be received in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when or as the performance obligations are satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Partner program revenue includes revenue associated to the drug creation phases of drug creation agreements. The Company refers to its customers as “partners” when describing their relationship in an agreement.
Partner program revenue
The Company’s drug creation agreements generally include multiple stages of drug creation that combined represent a single performance obligation. These agreements may include options for additional goods and services such as readying the technology to transfer to the partner and licensing terms. The transaction prices for these arrangements include fixed and variable consideration for the single performance obligation as well as variable consideration for success-based achievements. Any variable consideration is constrained to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Primarily all of the Company’s contracts with its partners include an enforceable right to payment. While there is no alternative use to the Company for the asset created, the agreements’ terms vary as to whether an enforceable right to payment exists for performance completed as of that date.
The Company measures progress toward the completion of the performance obligations satisfied over time using an input method based on actual cost incurred to date and estimated cost to complete at each reporting date to satisfy a performance obligation. This method provides an appropriate depiction of completed progress toward fulfilling its performance obligations for each respective arrangement. In certain drug creation agreements that require a portion of the contract consideration to be received in advance at the commencement of the contract, such advance payment is initially recorded as a contract liability.
Income taxes
The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability accounts are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are currently in effect. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized.
The Company files income tax returns in federal, state and various foreign tax jurisdictions.
The Company recognizes interest and penalties related to income tax matters as a component of tax expense. The Company did not record any interest or penalties related to income tax during the years ended December 31, 2025 and 2024.
We recognize uncertain tax positions taken or expected to be taken on a tax return. Tax positions are initially recognized when it is more likely than not that the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is more likely than not of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.
Research and development expenses
Research and development expenses include the personnel-related costs (comprised of salaries, benefits and share-based compensation), contract research services, contract manufacturing, consulting fees, laboratory supplies and facilities, and certain technology costs. These expenses are exclusive of depreciation and amortization. Research and development activities consist of continued development of the Company’s
Integrated Drug Creation platform, internal pipeline programs, and drug creation programs with partners. The Company derives improvements to its platform from each type of activity. Research and development efforts apply to the Company’s platform broadly and across programs.
Preclinical and clinical development costs
Preclinical and clinical development costs compose a component of research and development costs, in which we typically contract with third parties, including contract research organizations (CROs) and clinical data management organizations (CDMOs), to conduct and manage preclinical studies and clinical trials, research services, and clinical manufacturing services on our behalf. When billing terms under these contracts do not coincide with the timing of when the work is performed, we estimate our obligations for services provided but not yet billed as of the period end based on a number of factors that include, but are not limited to, our knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. Further, we accrue expenses related to clinical trials based on the status of participant enrollment and activity according to the related agreement. We monitor participant enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. We obtain information regarding unbilled services directly from outside service providers and perform procedures to support our estimates based on our internal understanding of the services provided to date. However, we may also be required to estimate these services based on information available to our internal preclinical and clinical and administrative staff if such information is not able to be obtained timely from our service providers.
Accrued preclinical and clinical development expenses are included in Accounts payable and accrued expenses on the consolidated balance sheets. In the event that advance payments are made to a CRO, CDMO or other outside service providers, the payments are recorded within prepaid expenses and other current assets on the consolidated balance sheets and subsequently recognized as research and development expense when the associated services are performed. If we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates, resulting in adjustments to expense in future periods.
Collaboration agreements
The Company analyzes its drug creation agreements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and that are exposed to significant risks and rewards dependent on the commercial success of such activities. Payments to and from the Company’s collaborators are presented within research and development expense on the consolidated statements of operations and comprehensive loss.
Stock-based compensation
Stock-based compensation includes compensation expense for stock options and restricted stock units granted to employees and non-employees and is measured on the grant date based on the fair value of the award and recognized over the requisite service period. The fair value of options to purchase common stock are measured using the Black-Scholes option-pricing model. The fair value of performance restricted stock units are measured using a Monte-Carlo simulation model and the expense is recorded using the accelerated expense attribution method. When determining the grant date fair value of stock-based awards, management considers whether an adjustment is required to the observable market price or volatility of the Company’s common stock that is used in the valuation as a result of material non-public information. The Company accounts for forfeitures as they occur.
Net Loss Per Share
Basic and diluted net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company was in a loss position for all periods presented, therefore basic net loss per share and diluted net loss per share are the same for all periods as the inclusion of all potential common securities outstanding would have been anti-dilutive.
Recent accounting pronouncements
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation, as well as provide additional information for reconciling items that meet a quantitative threshold. Further, the ASU requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-09 during the year ended December 31, 2025, on a prospective basis, which resulted in updated income tax disclosures. See Note 17: Income taxes in the accompanying notes to the consolidated financial statements for further detail.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new standard requires additional disclosure of the nature of expenses included in the income statement as well as disclosures about specific types of expenses included in the expense captions presented in the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of the ASU on its consolidated financial statements.
- Revenue recognition
Contract balances
Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of the satisfaction of performance obligations. As of December 31, 2025 and December 31, 2024, contract liabilities were $1.2 million and $1.1 million, respectively. During the year ended December 31, 2025, the Company recognized $1.1 million as revenue that had been included in deferred revenue at the beginning of the period. During the year ended December 31, 2024, the Company recognized $3.3 million, as revenue that had been included in deferred revenue at the beginning of the period.
Concentration of risk
During the year ended December 31, 2025, three partners represented 95% of total partner program revenue. During the year ended December 31, 2024, two partners represented 99% of total partner program revenue. For the years ended December 31, 2025 and 2024, substantially all partner program revenue was attributable to foreign partners.
- Collaborative arrangements
As of December 31, 2025, the Company has collaborative arrangements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin that involve joint research and development activities and for which the parties are exposed to significant risks and rewards dependent on the commercial success of such activities. The Company performs drug creation activities to co-develop product candidates. These arrangements include rights for the parties to share in the potential value created by the programs, as well as cost sharing which may result in payments and/or credits between the parties. The Company’s accounting policy is to present cost sharing payments to and from the Company’s collaborators within research and development expense on the consolidated statements of operations and comprehensive loss. The Company received $0.8 million of cost sharing payments and credits related to collaborative arrangements during the year ended December 31, 2025. The Company didnot have cost sharing payments and credits related to collaborative arrangements during the year ended December 31, 2024.
- Investments
Cash equivalents and marketable securities are classified as available-for-sale and are recorded at fair value on the consolidated balance sheets, with any unrealized gains and losses reported in accumulated other comprehensive loss, which is reflected as a separate component of stockholders’ equity on the Company’s consolidated balance sheets, until realized. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company considers all marketable securities to be current assets as they are available for use in current operations.
The amortized cost and fair value of investments are as follows (in thousands):
| December 31, 2025 | ||||
|---|---|---|---|---|
| Amortized cost | Gross unrealized gains | Gross unrealized losses | Fair market value | |
| Assets | ||||
| Money market funds | $14,410 | $— | $— | $14,410 |
| U.S. treasuries | 124,059 | 208 | — | 124,267 |
| Total | $138,469 | $208 | $— | $138,677 |
| Classified as: | ||||
| Cash equivalents | $14,410 | |||
| Marketable securities | 124,267 | |||
| Total | $138,677 | |||
| December 31, 2024 | ||||
|---|---|---|---|---|
| Amortized cost | Gross unrealized gains | Gross unrealized losses | Fair market value | |
| Assets | ||||
| Money market funds | $2,134 | $— | $— | $2,134 |
| U.S. treasuries | 71,151 | 61 | — | 71,212 |
| Total | $73,285 | $61 | $— | $73,346 |
| Classified as: | ||||
| Cash equivalents | $2,134 | |||
| Marketable securities | 71,212 | |||
| Total | $73,346 | |||
Proceeds from maturities of available-for-sale securities were $69.5 million and $177.1 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, the Company held $11.8 million of marketable securities with a remaining maturity of greater than one year. There wereno realized gains or losses on securities for the years ended December 31, 2025 and 2024.
- Fair value measurements
The Financial Accounting Standards Board (“FASB”) has defined fair value to establish a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1: Observable inputs such as quoted prices in active markets.
Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
When quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation hierarchy.
If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2 inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy.
The following tables summarize the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2025 and December 31, 2024 (in thousands):
| December 31, 2025 | ||||
|---|---|---|---|---|
| Level 1 | Level 2 | Level 3 | Total | |
| Assets: | ||||
| Debt Securities: | ||||
| Money market funds | $14,410 | $— | $— | $14,410 |
| U.S. treasuries | 6,873 | 117,394 | — | 124,267 |
| Total assets | $21,283 | $117,394 | $— | $138,677 |
| December 31, 2024 | ||||
|---|---|---|---|---|
| Level 1 | Level 2 | Level 3 | Total | |
| Assets | ||||
| Debt Securities: | ||||
| Money market funds | $2,134 | $— | $— | $2,134 |
| U.S. treasuries | — | 71,212 | — | 71,212 |
| Total assets | $2,134 | $71,212 | $— | $73,346 |
| Liabilities: | ||||
| Contingent consideration | $— | $— | $12,750 | $12,750 |
| Total liabilities | $— | $— | $12,750 | $12,750 |
In June 2021, the Company entered into a merger agreement with Totient, Inc. (“Totient”). Pursuant to the merger agreement, at closing, Totient shareholders received $40.0 million in cash, and 2,212,208 shares of the Company’s common stock, and became eligible to receive contingent consideration of $15.0 million in cash payable upon the achievement of specified milestones. As of December 31, 2024, the Company maintained a contingent consideration liability of $12.8 million, which was measured at fair value based on a probability-weighted approach using significant unobservable inputs (Level 3). In October 2025, the Company entered into an agreement with the selling stockholders of Totient to settle the contingent consideration liability for a payment of approximately $7.6 million and to release the remaining $8.7 million, held as restricted cash on the consolidated balance sheets, from escrow to the Company. In 2025, the Company recognized a $5.1 million gain on settlement in the consolidated statement of operations.
- Property and equipment, net
Property and equipment consist of the following (in thousands):
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Lab Equipment | $25,564 | $27,294 |
| Furniture, Fixtures and Other | 3,736 | 6,385 |
| Leasehold Improvements | 27,079 | 27,057 |
| Total Cost | 56,379 | 60,736 |
| Less accumulated depreciation and amortization | (35,519) | (31,569) |
| Property and equipment, net | $20,860 | $29,167 |
Depreciation expense was $8.4 million and $10.0 million for the years ended December 31, 2025 and 2024, respectively.
During the years ended December 31, 2025 and 2024, the Company determined certain laboratory equipment met all of the prescribed criteria required to classify it as held-for-sale. The Company determined the carrying value exceeded the fair value less costs to sell each asset, which resulted in a write down of $0.7 million and $1.4 million for the year ended December 31, 2025 and 2024, respectively, presented within research and development expense on the consolidated statement of operations and comprehensive loss. As of December 31, 2025 and December 31, 2024, $0.1 million and $0.7 million, respectively, of lab equipment is classified as current assets held-for-sale within prepaid expenses and other current assets on the consolidated balance sheets as the disposal is expected to be consummated within one year of the balance sheet date.
- Intangibles, net
Intangible assets are as follows (in thousands):
| December 31, 2025 | December 31, 2024 | |||||
|---|---|---|---|---|---|---|
| Gross Assets | Accumulated Amortization | Net | Gross Assets | Accumulated Amortization | Net | |
| AI Engine | 2,507 | (2,478) | 29 | 2,507 | (1,977) | 530 |
| Monoclonal antibody library | 46,300 | (10,585) | 35,715 | 46,300 | (8,270) | 38,030 |
| Developed software platform and the related methods patents | 8,300 | (2,530) | 5,770 | 8,300 | (1,977) | 6,323 |
| Intangible assets, net | $57,107 | $(15,593) | $41,514 | $57,107 | $(12,224) | $44,883 |
Amortization expense related to intangible assets was $3.4 million for the years ended December 31, 2025 and 2024 and is reflected within depreciation and amortization expense on the consolidated statements of operations and comprehensive loss.
The weighted-average remaining useful lives of the Company’s acquired intangible assets as of December 31, 2025 are as follows:
| | |
|---|---|
| Weighted-Average Remaining Useful Lives (years) | |
| Monoclonal antibody library | 15.4 |
| Developed software platform and the related methods patents | 10.4 |
Future amortization expense for the Company’s intangible assets as of December 31, 2025 is estimated as follows (in thousands):
| Years Ending December 31: | |
|---|---|
| 2026 | $2,898 |
| 2027 | 2,868 |
| 2028 | 2,868 |
| 2029 | 2,868 |
| 2030 | 2,868 |
- Accounts payable and accrued expenses
Total accounts payable and accrued expenses reported on the consolidated balance sheets as follows (in thousands):
| For the Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Accounts payable | $2,756 | 2,948 |
| Accrued compensation | 6,615 | 5,954 |
| Accrued preclinical and clinical development expenses | 6,350 | 580 |
| Accrued other | 3,627 | 967 |
| Total accounts payable and accrued expenses | $19,348 | $10,449 |
- Leases
Facility leases
The Company leases its corporate headquarters and primary research and development facility located in Vancouver, Washington in a 77,974 square foot facility that includes general administrative office and laboratory space. The corporate headquarters lease initially commenced in December 2020, amended in 2021, and ends in April 2028, with an option to renew the lease for an additional five-year term, at then-current market rates. As part of the lease agreement, the lessor provided tenant incentives in the amount of $3.1 million. For the Company’s facility lease agreement, the Company is responsible for taxes, insurance and maintenance costs. The Company is party to certain short-term leases having a term of twelve months or less at the commencement date.
The components of lease expense are as follows (in thousands):
| For the Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating lease cost | 1,629 | 1,716 |
| Variable lease cost | 385 | 446 |
| Short-term lease cost | 138 | 203 |
| $2,152 | $2,365 | |
| Cash paid for amounts included in the measurement of lease liabilities: | ||
| Operating cash flows related to operating leases | $2,036 | $2,266 |
Future undiscounted lease payments for the Company’s lease liabilities as of December 31, 2025 are as follows (in thousands):
| Operating leases | |
|---|---|
| 2026 | $2,098 |
| 2027 | 2,101 |
| 2028 | 672 |
| Total future lease payments | 4,871 |
| Less: Imputed interest | (442) |
| Present value of lease liabilities | $4,429 |
Additional information related to the Company’s leases is as follows:
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Weighted average remaining lease term (in years) | ||
| Operating leases | 2.2 | 3.2 |
| Weighted average discount rate | ||
| Operating leases | 8% | 8% |
- Commitments and contingencies
The Company has access to compute capacity and other services through an agreement with Oracle Cloud Infrastructure (OCI) through early 2028. The remaining financial commitments for the years 2026, 2027, and 2028 are $4.6 million, $8.3 million, and $2.3 million, respectively.
As of December 31, 2025, future lease payments are secured by an irrevocable standby letter of credit totaling $1.1 million. The irrevocable standby letter of credit is expected to be pledged for the full lease term which extends through April 2028 for the Company’s headquarter facility.
- Common stock
At-the-market offering
In June 2023, the Company entered into a Sales Agreement with Cowen and Company, LLC, as Sales Agent (the “Prior Sales Agreement”), with respect to an “at the market offering” program under which the Company had the ability to offer and sell, from time to time, shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $100.0 million through the Sales Agent. The Company agreed to pay the Sales Agent a commission up to 3.0% of the gross sales proceeds of any shares sold under the Prior Sales Agreement. During the year ended December 31, 2025, the Company issued and sold 10,377,752 shares and received $35.7 million in net proceeds from the sale of securities pursuant to the Prior Sales Agreement.
In August 2025, the Company entered into a Sales Agreement with TD Securities (USA) LLC, as Sales Agent (the “Sales Agreement”), with respect to an “at the market offering” program under which the Company may offer and sell, from time to time, shares of its common stock having an aggregate offering price of up to $100.0 million through the Sales Agent. The Company has agreed to pay the Sales Agent a commission of up to 3.0% of the gross proceeds of any shares sold under the Sales Agreement. Upon execution, the Sales Agreement terminated and superseded the Prior Sales Agreement in its entirety. During the year ended December 31, 2025, the Company issued and sold 927,855 shares and received $3.5 million in net proceeds from the sale of securities pursuant to the Sales Agreement.
Private investment in public equity
In January 2025, the Company entered into a strategic collaboration with Advanced Micro Devices, Inc. (AMD) and sold an aggregate of 5,714,285 shares of the Company’s common stock to AMD for net proceeds of $20.0 million through a private investment in public equity (PIPE). This strategic collaboration with AMD has a goal to optimize the performance of AMD Instinct TM accelerators and ROCm TMsoftware to support the Company’s AI drug creation, including itsde novo antibody design models. The issuance of stock to AMD was at a premium of approximately $2.5 million over the market price on the issuance date. The premium was recorded to accrued expenses and other long-term liabilities on the consolidated balance sheet and will be recognized as a credit to research and development expense over the collaboration term. The amortization of the premium was $0.7 million for the year ended December 31, 2025.
- Stock-based compensation
The Company grants stock options, restricted stock units, and stock appreciation rights (“SARs”) under the 2021 Stock Option and Incentive Plan (“2021 Plan”) and the 2023 Inducement Plan (the “2023 Inducement Plan”). On January 1, 2025, the number of shares of common stock reserved for future issuance under the 2021 Plan was increased by 5,768,113 shares pursuant to an automatic annual increase. As of December 31, 2025,6,458,888 shares were available for issuance under the 2021 Plan. As of December 31, 2025,1,724,200 shares were available for issuance under the 2023 Inducement Plan.
Total stock-based compensation expense related to the Company’s stock-based awards was recorded in the consolidated statements of operations and comprehensive loss as follows (in thousands):
| For the Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Research and development | $7,912 | $7,426 |
| Selling, general and administrative | 10,440 | 12,043 |
| Total stock-based compensation expense | $18,352 | $19,469 |
Stock Options
Stock options generally vest 25% after one year from the date of the grant with the remainder vesting monthly over the following three-year period or ratably over three years in three equal installments. The Company recognizes forfeitures as they occur and uses the straight-line expense recognition method. Activity for stock options is shown below:
| Number of Options | Weighted Average Exercise Price per Share | Weighted Average Remaining Contractual Term (in years) | Aggregate Intrinsic Value (in thousands $) | |
|---|---|---|---|---|
| Outstanding at December 31, 2024 | 19,177,571 | $3.39 | 7.6 | $7,317 |
| Granted | 6,977,633 | 3.16 | ||
| Exercised | (1,296,120) | 2.31 | 2,399 | |
| Canceled/Forfeited | (3,182,252) | 3.04 | ||
| Expired | (960,321) | 7.02 | ||
| Outstanding at December 31, 2025 | 20,716,511 | 3.27 | 7.5 | 14,997 |
| Exercisable at December 31, 2025 | 10,109,911 | $3.32 | 6.4 | $9,841 |
| Vested and expected to vest as of December 31, 2025 | 20,706,986 | $3.27 | 7.5 | $14,974 |
The weighted-average grant date fair value of stock options granted during the years ended December 31, 2025 and 2024 was $2.26 and $3.00, respectively. The aggregate grant date fair value of options vested during the years ended December 31, 2025 and 2024 was $11.2 million and $9.4 million, respectively. As of December 31, 2025, total unrecognized stock-based compensation related to stock options was $18.7 million, which the Company expects to recognize over a remaining weighted average period of 2.0 years.
Determination of Fair Value
The estimated grant-date fair value of the Company’s stock options was calculated using the Black-Scholes option pricing model, based on the following assumptions:
| For the Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Expected term (in years) | 5.5-6.1 | 5.5-6.1 |
| Volatility | 90%-92% | 81%-84% |
| Risk-free interest rate | 3.6%-4.4% | 3.5%-4.6% |
| Dividend Yield | —% | —% |
The fair value of each stock option was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires judgment and estimation by management.
Expected Term—The Company’s historical option exercise data is limited and did not provide a sufficient basis upon which to estimate an expected term. The expected term for options was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award.
Expected Volatility—As we do not have sufficient trading history for our common stock, the expected volatility was derived from a blended approach of the Company and its industry peers’ historical stock volatilities. These companies are considered to be comparable to the Company’s business over a period equivalent to the expected term of the stock-based awards.
Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the stock options’ expected term.
Expected Dividend Rate—The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock underlying its stock options in the foreseeable future.
Restricted stock units
Restricted stock units subject to time-based vesting generally vest over a term of 1-4 years. The Company recognizes forfeitures as they occur and uses the straight-line expense recognition method. Activity for restricted stock units is shown below:
| Number of Shares | Weighted Average Grant Date Fair Value | |
|---|---|---|
| Unvested as of December 31, 2024 | 3,711,710 | $3.12 |
| Granted | 1,712,162 | 3.19 |
| Vested | (935,682) | 2.77 |
| Forfeitures | (698,556) | 2.70 |
| Unvested as of December 31, 2025 | 3,789,634 | $3.32 |
The weighted-average grant date fair value of restricted stock units granted during the years ended December 31, 2025 and 2024 was $3.19 and $3.93 per share, respectively. The aggregate grant date fair value of restricted stock units vested during the years ended December 31, 2025 and 2024 was $2.6 million and $1.0 million, respectively
As of December 31, 2025, there was $4.5 million of unrecognized compensation expense related to the outstanding restricted stock units expected to be recognized over a remaining weighted-average period of 1.7 years.
Restricted stock unit award with market conditions
In March 2024, the Company granted 1,500,000 performance restricted stock units to its Founder and Chief Executive Officer that contained market conditions (the “2024 Market Award”). Subject to the holder’s continued service, the 2024 Market Award provided for vesting in tranches once the Company’s closing stock price meets or exceeds certain thresholds established by the Company’s Compensation Committee of the Board of Directors. The original grant-date fair value of the 2024 Market Award of $5.5 million was determined using a Monte Carlo simulation model using an expected volatility of 97% and risk-free rate of 4.5%. The stock-based compensation expense was recognized over the derived service period for each tranche over periods up to 1.3 years. As of December 31, 2025, none of the stock price thresholds for the 2024 Market Award had been met resulting in no shares vesting. Any unvested tranches of the 2024 Market Award will expire in March 2027 if the vesting conditions are not met.
Stock Appreciation Rights
In January 2021, the Company issued SARs that are contingent upon a liquidity event that is not probable of occurrence; accordingly, no compensation expense has been recognized for these awards. The aggregate intrinsic value of the 394,736 SARs outstanding as of December 31, 2025 is $1.4 million based on the Company’s closing stock price of $3.49 per share as reported on the Nasdaq Global Select Market on such date.
Under the 2020 Plan and 2021 Plan, the Company has also granted a limited quantity of cash-settled SARs to certain employees and consultants based outside the United States. As of December 31, 2025,178,471 of these SARs were outstanding with a weighted average exercise price of $4.34 per share. The fair value is remeasured at the end of each reporting period based on the Company’s stock price, with remeasurements reflected as an adjustment to compensation expense in the consolidated statements of operations and comprehensive loss for such period. As of December 31, 2025 and December 31, 2024, the Company had recognized a less than $0.1 million liability for SARs classified within other long-term liabilities on the consolidated balance sheets.
Employee Stock Purchase Plan
In July 2021, the Company’s Board of Directors adopted the 2021 Employee Stock Purchase Plan (“2021 ESPP”). The ESPP allows eligible employees to purchase shares of the Company’s common stock through payroll deductions of up to 15% of their regular compensation at a discount of 85% of the fair market value of the Company’s common stock on the first day or last day, whichever is less, of the applicable offering period, subject to any plan limitations. On January 1, 2025, the number of shares of common stock reserved for issuance under the 2021 ESPP was increased by 1,153,622 shares pursuant to an automatic annual increase. As of December 31, 2025,3,132,960 shares were available for issuance under the 2021 ESPP.
- Employee benefit plans
The Company sponsors a 401(k) tax-deferred savings plan for all U.S. employees who meet certain eligibility requirements. Participants may contribute, on a pre-tax or post-tax basis, a percentage of their annual compensation, not to exceed a maximum contribution amount pursuant to Section 401(k) of the Internal Revenue Code. The Company match is 100% of the employees’ first contribution of 3%, plus 50% of the next 2% of eligible compensation contributed by the employee, up to a maximum Company match of 4% of compensation for each employee.
The Company sponsors a retirement plan for employees of Absci GmbH, the Company’s wholly-owned subsidiary based in Switzerland. The Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return.
The Company contributed $1.3 million and$1.2 millionto both plans in the aggregate for the years ended December 31, 2025 and December 31, 2024, respectively.
- Net loss per share
Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period.
The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented.
The following potentially dilutive securities, presented based on amounts outstanding at period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders because including them would be anti-dilutive:
| For the Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Stock options | 20,716,511 | 19,177,571 |
| Restricted stock units | 3,789,634 | 3,711,710 |
| Unvested restricted stock | — | 41,177 |
| Employee stock purchase plan | 69,411 | 102,233 |
| Total | 24,575,556 | 23,032,691 |
- Segment reporting
The Company hasone reportable segment.
The Company’s Chief Operating Decision Maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating performance. When evaluating the Company’s financial performance, the CODM regularly reviews total expenses by expense category and the CODM makes decisions using this information on a consolidated basis. There are no other measures of profitability used by the CODM, other than those disclosed in these consolidated financial statements.
The table below is a summary of the significant segment expenses (in thousands) provided to the Company’s CODM on a regular basis:
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Drug creation programs and platform (1) | $20,358 | $16,515 |
| External preclinical and clinical development (2) | 22,403 | 9,336 |
| Personnel (3) | 40,111 | 38,558 |
| Stock-based compensation | 18,352 | 19,469 |
| General & administrative | 15,506 | 14,947 |
| Depreciation and amortization | 11,742 | 13,389 |
| Other (gain)/loss, net (4) | (5,355) | 1,208 |
| Total operating expenses | $123,117 | $113,422 |
(1) “Drug creation programs and platform” consists of research and development costs incurred related to the Company’s internally developed programs and drug creation partnership programs for activities prior to the nomination of a development candidate and the continued development of the Company’s Integrated Drug Creation platform.
(2) “External preclinical and clinical development” expense consists of external costs incurred following the Company’s nomination of a development candidate, including all subsequent contract research services, contract manufacturing, consulting fees, and other external costs related to preclinical and clinical development.
(3) “Personnel” expense consists of all employee wages, taxes, benefits, severance, other employee related costs.
(4) “Other (gain)/loss, net” consists of non-routine gains and losses. For the year ended December 31, 2025 these include gain on settlement of the Company’s contingent consideration and a net gain on sales of property and equipment. For the year ended December 31, 2024, these include a net loss on sales of property and equipment.
- Income taxes
Provision for income taxes:
The Company incurred net losses for the years ended December 31, 2025 and 2024.
The significant components of income tax expense (benefit) are as follows (in thousands):
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Current expense / (benefit) | ||
| State | $(72) | $2 |
| Foreign | 239 | 133 |
| Total current expense | 167 | 135 |
| Deferred benefit | ||
| Federal | (98) | (65) |
| Total deferred benefit | (98) | (65) |
| Total expense / (benefit) | ||
| Federal | (98) | (65) |
| State | (72) | 2 |
| Foreign | 239 | 133 |
| Total expense | $69 | $70 |
The components of income (loss) before income taxes by tax jurisdiction for the years ended December 31, 2025 and 2024 are as follows (in thousands):
| 2025 | 2024 | |
|---|---|---|
| United States | $(117,796) | $(104,682) |
| Foreign | 2,682 | 1,646 |
| Loss before income taxes | $(115,114) | $(103,036) |
The income tax expense for the years ended December 31, 2025 and 2024 primarily relate to state taxes and taxes in foreign jurisdictions, offset by the change in valuation allowance.
The Company adopted ASU 2023-09 for the year ended December 31, 2025 on a prospective basis. A reconciliation between tax expense at the statutory tax rate applicable to income of the Company and the actual tax expense as reported in the consolidated statements of operations is as follows (in thousands, except for percentages):
| Amount | Percent | |
|---|---|---|
| Income taxes (benefit) at statutory federal rate | $(24,174) | 21.0% |
| State and local taxes, net of federal income tax effect* | (57) | — |
| Foreign tax effects | (325) | 0.3 |
| Effect of cross-border tax laws | ||
| Global intangible low-taxed income | 1,462 | (1.3) |
| Tax Credits | ||
| R&D Tax Credits | (2,092) | 1.8 |
| Changes in valuation allowance | 24,299 | (21.1) |
| Nontaxable or nondeductible items | 926 | (0.8) |
| Changes in unrecognized tax benefits | 523 | (0.5) |
| Other | (493) | 0.4 |
| Provision (benefit) for income taxes | $69 | (0.1)% |
| *The state that contributes to the majority (greater than 50%) of the tax effect in this category is Massachusetts. | ||
The following table is a reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate for the year ended December 31, 2024, in accordance with the guidance prior to the adoption of ASU 2023-09:
| Statutory federal income tax rate | 21.0% |
|---|---|
| State taxes, net of federal benefits | 0.1% |
| Rate Adjustment | (2.1)% |
| Section 162(m) Limitation | (1.5)% |
| Impairment | —% |
| Deemed Foreign Inclusion | (0.3)% |
| Stock Compensation | 0.1% |
| Return-to-provision | (2.7)% |
| Research and development credit | 2.0% |
| Tax Contingencies, net of reversals | (0.5)% |
| Tax Cuts and Jobs Act | —% |
| Change in valuation allowance | (16.1)% |
| Other | (0.1)% |
| Effective Income tax rate | (0.1)% |
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and amounts used for income tax purposes.
Significant components of the Company’s deferred income tax assets and liabilities as of December 31, 2025 and 2024 are as follows (in thousands):
| 2025 | 2024 | |
|---|---|---|
| Deferred tax assets: | ||
| Net operating losses | $76,333 | $49,467 |
| Research and development credits | 8,926 | 7,357 |
| Capitalized research and development expenses | 25,052 | 26,904 |
| Stock-based compensation | 4,044 | 3,274 |
| Lease liability | 1,024 | 1,291 |
| Accrued expenses and other | 1,402 | 853 |
| Gross deferred tax assets | 116,781 | 89,146 |
| Less valuation allowance | (106,171) | (77,976) |
| Total deferred tax assets | 10,610 | 11,170 |
| Deferred tax liabilities: | ||
| Property and equipment | (363) | (927) |
| Intangibles | (9,595) | (9,475) |
| Right-of-use lease asset | (675) | (889) |
| Gross deferred tax liabilities | (10,633) | (11,291) |
| Deferred tax liabilities, net | $(23) | $(121) |
As of December 31, 2025, the Company has federal and state net operating loss carryforwards of approximately $323.5 million and $143.6 million, respectively, to offset against future taxable income. Under the Tax Cuts and Jobs Act of 2017 (“TCJA”), federal net operating losses incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an 80% of taxable income limitation. NOLs generated prior to 2018 are eligible to be carried forward up to 20 years and have no taxable income limitation. The Company has $322.1 million of federal net operating losses that do not expire and $1.4 million that will expire in 2037. State net operating losses can be carried forward for 5 to 20 years depending on the jurisdiction and will begin to expire in years 2039-2045. The company also has Federal research credit carryforwards of approximately $12.0 million that will begin to expire in 2039.
In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December 31, 2025, the Company has recorded a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance increased $28.2 million during the year ended December 31, 2025 and $16.7 million during the year ended December 31, 2024.
Under the provisions of the Internal Revenue Code, certain substantial changes in the company's ownership may result in a limitation on the amount of net operating loss carryforwards and research and development credit carryforwards which could be utilized annually to offset future taxable income and taxes payable. We completed a study of our changes in ownership through December 31, 2025 and determined that no material limitations exist on the utilization of the Company’s tax attributes.
The Company maintained undistributed earnings overseas as of December 31, 2025, and the Company believed the funds held by all non-U.S. subsidiaries will be permanently reinvested outside of the U.S. However, if these funds were repatriated to the U.S. or used for U.S. operations, the Company may be subject to withholding taxes in the foreign countries. The Company’s unrepatriated earnings are not subject to federal income tax in the U.S. when distributed.
The following is a reconciliation of the Company’s unrecognized tax benefits (in thousands):
| 2025 | 2024 | |
|---|---|---|
| Balance at January 1 | $2,564 | $2,116 |
| Additions Based On Tax Positions Related to Current Year | 477 | 507 |
| Additions Based On Prior Tax Positions | 46 | (59) |
| Balance at December 31 | $3,087 | $2,564 |
The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. The Company had unrecognized tax benefits of $3.1 million and $2.6 million as of December 31, 2025 and 2024, respectively.
The Company recognizes penalties and interest related to unrecognized tax benefits as a component of income tax expense. All unrecognized tax benefits would currently not have an impact on the effective rate if recognized. The Company does not anticipate any significant increases or decreases in its uncertain tax positions within the next twelve months.
As of December 31, 2025 the Company’s statutes of limitations are open for all federal and state years filed after the years ended December 31, 2022 and 2021, respectively. Net operating loss and credit carryforwards from all years are subject to examination and adjustments for the three years following the year in which the carryforwards are utilized. The Company is not currently under examination by any taxing authority.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.